by Kwon Jaehee
Published 19 Apr.2022 10:34(KST)
[Asia Economy Reporter Kwon Jaehee] BridgeBio announced on the 19th that it has signed a technology licensing agreement for a candidate drug for idiopathic pulmonary fibrosis (IPF) treatment with Shaperon Co., Ltd.
The contract amount includes an upfront payment of 2 billion KRW and a milestone technology fee of 28 billion KRW.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.